GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback